<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2016-06-07 14:09:04Medicine Health Clinical medicine Rare diseases Angiology Lymphangioleiomyomatosis Benign neoplasms Signal transduction Tuberous sclerosis Angiomyolipoma Sirolimus Mechanistic target of rapamycin |
Add to Reading List |
Microsoft Word - AJP Jul16 PR Yue FINAL.docx | Microsoft Word - AJP Jul16 PR Yue FINAL.docxDocID: 1qQbV - View Document |
| Birt-Hogg-Dubé syndrome: diagnosis and managementDocID: 1ovL7 - View Document |
| The LAM Foundation 2014 Lymphangioleiomyomatosis International Research ConferenceDocID: 1lxHf - View Document |
| In renal transplant patients at high-immunologic risk • Rapamune and Cyclosporine Combination Therapy (for the first 12 months post-transplantation): One loading dose of up to 15 mg on day 1, followed by daily maintenDocID: 1lhSD - View Document |
| Articles Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trialDocID: 1eEee - View Document |